Table 3.
Survey question conditions and disciplines.
| Question | Condition | Discipline | Mean (SD) Agreement |
|---|---|---|---|
| 1. A patient’s genetic profile can influence their risk of CKD progression | CKD | Knowledge | 4.2 (0.6) |
| 2. Genetic testing will help me to better diagnose the cause of my patient’s CKD | CKD | Action | 3.6 (0.8) |
| 3. Patients and their families can benefit from understanding genetic contributors to their CKD. | CKD | Attitude | 4.0 (0.6) |
| 4. Genetic testing of my CKD patients provides information that may change my therapeutic management of patients. | CKD | Action | 3.8 (0.8) |
| 5. Genetic testing of my CKD patients provides information that changes dialysis preparation strategies in my patients. | CKD | Action | 3.3 (0.9) |
| 6. Genetic testing for CKD provides information that will help me delay or halt the progression of CKD in my patients. | CKD | Action | 3.5 (0.8) |
| 7. The presence of 2 APOL1 risk alleles in a potential donor would impact the decision to donate a kidney for transplantion. | CKD | Action | 3.8 (0.8) |
| 8. The presence of 2 APOL1 risk alleles in a patient would impact my management of Focal Segmental Glomerulosclerosis (FSGS). | CKD | Action | 3.6 (0.7) |
| 9. I personally review and discuss a family history (taken by myself or a physician-in-training/nurse/physician extender) for every patient I meet in the hospital or in a clinic. | General | Attitude | 4.1 (0.8) |
| 10. Genetic testing is a valuable complement to a detailed family history. | General | Knowledge | 3.7 (0.7) |
| 11. Discussing genetic testing results with patients will lead to increased patient anxiety. | General | Attitude | 3.1 (1.1) |
| 12. Nephrologists should be trained to interpret and counsel patients on genetic variants that contribute to CKD. | CKD | Attitude | 4.1 (0.6) |
| 13. Genetic counselors should be trained to interpret and counsel patients on genetic variants that contribute to CKD. | CKD | Attitude | 4.2 (0.6) |
| 14. There is sufficient evidence to implement genetic testing in patients with CKD. | CKD | Knowledge | 3.2 (0.9) |
| 15. The benefits of genetic testing outweigh the risks to patients. | General | Knowledge | 3.8 (0.7) |
| 16. I feel comfortable discussing genetic test results with patients. | General | Attitude | 3.1 (1.1) |
| 17. A discussion of genetic test results is too time-consuming for a clinic encounter. | General | Attitude | 3.3 (1.0) |
| 18. Genetic testing may help me better treat my patient’s hypertension. | HTN | Knowledge | 3.8 (0.8) |
| 19. A patient’s genetic profile can influence their therapeutic response to antihypertensives. | HTN | Knowledge | 4.0 (0.7) |
| 20. Genetic testing of my HTN patients provides information that may change the antihypertensives that I prescribe. | HTN | Action | 3.8 (0.9) |
| 21. Genetic testing of my HTN patients provides information that may help me better achieve the recommended blood pressure goals. | HTN | Action | 3.7 (0.8) |
| 22. Provided no contraindications exist, I would follow the dosing suggestions of a pharmacogenomic test for a NEW prescription if the test indicated an alternate medication or dose was appropriate. | HTN | Action | 4.0 (0.7) |
| 23. Provided no contraindications exist, I would change an EXISTING prescription, one in which the patient had a stable response, in order to follow the dosing suggestions of a pharmacogenomic test if the test indicated an alternate medication or dose was appropriate. | HTN | Action | 3.4 (0.9) |
The averages and standard deviations were found within the context of one nonresponse for both questions 4 and 5. CKD: Chronic Kidney Disease; HTN: Hypertension.